GlassScriptPhysician profile
David I Kurss
NPI 1720029002
$25,350.06
in general payments reported to CMS, 2019-2025
32 companies · $1,573 in 2025
The $1,573 reported for 2025 was more than what 88% of Gynecology providers received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,012 · 2020: $219 · 2021: $532 · 2022: $955 · 2023: $14K · 2024: $3,591 · 2025: $1,573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Food and Beverage: $1,503 · Travel and Lodging: $262 · Education: $99.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,767.50 |
| Food and Beverage | $1,503.40 |
| Travel and Lodging | $262.00 |
| Education | $99.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $18,998.85 | 2019-2025 | Veozah, Myrbetriq |
| Amag Pharmaceuticals, INC. | $3,516.30 | 2019 | |
| Abbvie INC. | $714.01 | 2019-2024 | |
| Amgen INC. | $529.70 | 2019-2024 | Prolia, Evenity, Enbrel |
| Novo Nordisk INC | $290.79 | 2019-2021 | |
| Millicent US INC | $181.75 | 2019-2025 | Intrarosa, Femring, Femlyv |
| Myovant Sciences INC. | $124.99 | 2021 | |
| Exact Sciences Corporation | $123.19 | 2023-2025 | Cologuard Collection Kit |
| Agile Therapeutics, INC. | $122.31 | 2021 | |
| Hologic Sales and Service, LLC | $86.34 | 2019-2025 | Aptima, Thinprep 2000 Processor |
| Therapeuticsmd, INC. | $71.33 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $59.82 | 2025 | Acthar |
| Mayne Pharma Commercial LLC | $58.65 | 2025 | |
| Ucb, INC. | $53.11 | 2024-2025 | Bimzelx |
| Pfizer INC. | $50.81 | 2021-2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma Global Development | $47.11 | 2023-2025 | Veozah |
| Meditrina | $37.37 | 2021 | |
| Gilead Sciences, INC. | $36.59 | 2023 | |
| Vertical Pharmaceuticals, LLC | $30.55 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $27.80 | 2025 | Saphnelo |
| Merck Sharp & Dohme LLC | $27.59 | 2024 | Gardasil, Gardasil 9 |
| Evofem Biosciences, INC. | $24.10 | 2021 | |
| Coopersurgical, INC. | $21.13 | 2024 | Paragard T 380a |
| Takeda Pharmaceuticals U.S.A., INC. | $15.31 | 2021 | |
| Lupin INC. | $14.66 | 2019 | |
| Ironwood Pharmaceuticals, INC | $14.21 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.94 | 2022 | |
| Medtronic, INC. | $11.97 | 2022 | |
| Janssen Biotech, INC. | $11.96 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $11.73 | 2019 | |
| Endo Pharmaceuticals INC. | $11.69 | 2019 | |
| Allergan, INC. | $11.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kurss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.